BA
FATE icon

BlackRock Advisors’s Fate Therapeutics FATE Stock Holding History

BlackRock Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$10K Hold
4,030
– – ﹤0.01% 3565
2016
Q3 		$13K Hold
4,030
– – ﹤0.01% 3531
2016
Q2 		$7K Sell
4,030
-4,781
-54% -$8.67K ﹤0.01% 3631
2016
Q1 		$16K Buy
8,811
+3,112
+55% +$6.41K ﹤0.01% 3482
2015
Q4 		$19K Buy
5,699
+1,669
+41% +$7.01K ﹤0.01% 3499
2015
Q3 		$21K Buy
4,030
+2,862
+245% +$19.5K ﹤0.01% 3505
2015
Q2 		$8K Buy
+1,168
New +$6.99K ﹤0.01% 3636

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock Advisors's FATE Position: Q4 2016 in Review

BlackRock Advisors held its Fate Therapeutics (FATE) position steady in Q4 2016 at 4,030 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #3565.

BlackRock Advisors first reported a position in FATE in Q2 2015 and has held it in 7 quarters since. The position peaked at $21K in Q3 2015. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

  • BlackRock Advisors held 4,030 shares of Fate Therapeutics worth $10K as of Q4 2016.
  • BlackRock Advisors left its Fate Therapeutics share count unchanged in Q4 2016.
  • Fate Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3565 holding.
  • BlackRock Advisors first reported a position in Fate Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Advisors's Fate Therapeutics position peaked at $21K in Q3 2015.
  • 37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.